Dextech Medical AB
Research Dextech Medical AB (DEX.ST) on Bullrun: market cap SEK 184.86M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDEX.ST
- ExchangeXSAT
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 184.86M
- Financial periodQ2 2026
- RevenueSEK 0
- Net income-SEK 1.84M
- Free cash flow-SEK 42.00K
Valuation Snapshot
latest market cap is SEK 184.86M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | SEK 184.86M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Dextech Medical AB
Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer in Sweden. The company's lead candidate, OsteoDex, which has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Dextech Medical AB's market cap?
Dextech Medical AB's market capitalization is SEK 184.86M.
What does Dextech Medical AB do?
Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer in Sweden. The company's lead candidate, OsteoDex, which has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma.